Kyle Piskel - 04 Feb 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Reporting relationship: Chief Financial Officer
Issuer ticker: ADPT
Reported as of: 04 Feb 2026
Net transaction value: -$13,556
SEC form: 4
Accepted by SEC: 06 Feb 2026, 19:30:18 UTC
Prior SEC filing: 14 Jan 2026
Next SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Kyle Piskel

Key filing fact

Kyle Piskel filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 06 Feb 2026.

Key facts

This page summarizes Kyle Piskel's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 19:30.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: -$13,556.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780662 Primary reporting owner

PISKEL KYLE

Relationship: Chief Financial Officer
Address: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE
Signature: /s/ Kyle Piskel
Signature date: 06 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADPT transaction

Common Stock

Options Exercise

Transaction value: $26,040
Shares: +2,145
Change %: +0.99%
Price: $12.14
Shares after: 218,782
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F1

ADPT transaction

Common Stock

Sale

Transaction value: $39,597
Shares: -2,145
Change %: -0.98%
Price: $18.46
Shares after: 216,637
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADPT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -2,145
Change %: -50%
Price: $0.000000
Shares after: 2,146
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,145
Exercise price: $12.14
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

Footnote F2

The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.